Supernus Pharma (SUPN) Tops Q4 EPS by 21c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Supernus Announces Record Full Year 2018 Financial Results
February 26, 2019 4:56 PM ESTFourth quarter 2018 total revenue of $115.9 million, a 31% increase over 2017, and fourth quarter 2018 net product sales of $113.5 million, a 32% increase over 2017.Fourth quarter 2018 operating earnings of $39.9 million, a 16% increase over 2017.Full year 2018 total revenue of $408.9 million, a 35% increase over 2017. Full year 2018 net product sales of $399.9 million, a 36% increase over 2017.Full year 2018 operating earnings of $144.4 million, a 45% increase over 2017.Positive results from three Phase III studies for SPN-812 in ADHD announced in December 2018.Oxtellar XR® launched in January 2019 with expanded indication to include monotherapy for partial seizures.
ROCKVILLE, Md., Feb. 26, 2019 (GLOBE NEWSWIRE) --... More
